Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

1.1K
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
1.1K
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

1.5K
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
1.5K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

1.1K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
1.1K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

1.7K
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
1.7K
Analgesia and Pain Management01:25

Analgesia and Pain Management

3.3K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
3.3K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

365
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
365

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Barettin Suppresses Pancreatic Ductal Adenocarcinoma Proliferation via Topoisomerase IIα Inhibition.

Marine drugs·2026
Same author

Temporal multi-omic exploration of the ventral tegmental area in chronic pain and passive coping behaviors.

iScience·2026
Same author

Postoperative multimodal pain management: a narrative review of current practices, clinical and educational gaps, and future directions.

Frontiers in anesthesiology·2026
Same author

Barettin, a Nonopioid, Nonhallucinogenic Marine Natural Product with Antihyperalgesic Properties Mediated by 5HT2A Inverse Agonism.

Journal of natural products·2026
Same author

A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor-Hair Serum for the Prevention of Chemotherapy-Induced Alopecia.

Journal of cosmetic dermatology·2026
Same author

Evaluation of Burn Depth using Indocyanine Green: Discrepancies Between Macroscopic Visualization and the Microenvironment.

Plastic and reconstructive surgery·2026
Same journal

Divergent Biology and Outcomes of Somatic Transformations in Germ Cell Tumors.

The oncologist·2026
Same journal

Modernizing Disease Assessment in Prostate Cancer Trials: The Prostate Cancer Working Group 4 Framework.

The oncologist·2026
Same journal

Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial.

The oncologist·2026
Same journal

Dose-Expansion Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors.

The oncologist·2026
Same journal

Comparison of Allo-HSCT outcomes after CAR-T therapy versus chemotherapy in pediatric patients with relapsed/refractory B-ALL: a retrospective study.

The oncologist·2026
Same journal

Patient, Care Partner, and Oncologist Perspectives on Clinically Important Survival Thresholds After Considering Time Toxicity in Advanced Cancer.

The oncologist·2026
See all related articles

Related Experiment Video

Updated: Apr 30, 2026

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

24.2K

Evaluation of Dronabinol to Decrease Opioid Use for Cancer-Induced Bone Pain.

Jennifer Segar1, Kiah Farr2, Mary Junak3

  • 1Next Oncology, Houston, USA.

The Oncologist
|April 28, 2026
PubMed
Summary
This summary is machine-generated.

Dronabinol, a cannabinoid receptor agonist, reduced opioid needs for cancer-induced bone pain in a pilot study. Patients experienced improved quality of life and pain management, suggesting potential for novel analgesics.

Keywords:
BiomarkersBone MetastasesCB2 agonistsCancer-induced bone painMetastatic Breast CancerOpiatesdronabinol

More Related Videos

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
09:28

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

18.9K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

765

Related Experiment Videos

Last Updated: Apr 30, 2026

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior
12:20

Use of the Operant Orofacial Pain Assessment Device OPAD to Measure Changes in Nociceptive Behavior

Published on: June 10, 2013

24.2K
A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
09:28

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

18.9K
Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents
03:43

Oromucosal as an Alternative Method for Administration of Cannabis Products in Rodents

Published on: August 22, 2025

765

Area of Science:

  • Oncology
  • Pain Management
  • Pharmacology

Background:

  • Breast cancer bone metastases (BM) cause significant cancer-induced bone pain (CIBP).
  • Opioids are the primary treatment for CIBP but have side effects.
  • Cannabinoid receptor agonists (CB2/CB1) show preclinical promise for reducing CIBP and bone degradation.

Purpose of the Study:

  • To evaluate the efficacy of adding CB2/CB1 agonists to opioid therapy for CIBP in breast cancer patients.
  • To determine if dronabinol can decrease opioid requirements in patients with BM.

Main Methods:

  • A single-arm study involving 14 breast cancer patients with BM on opioid therapy.
  • Patients received 10 mg dronabinol twice daily for 8 weeks.
  • Primary endpoint was the proportion of patients decreasing opioid use by ≥20%.

Main Results:

  • Four out of 14 evaluable patients met the primary endpoint, decreasing opioid use by ≥20%.
  • Significant improvements were reported in pain severity, quality of life, and insomnia.
  • A significant decrease in serum C-terminal telopeptide levels was observed.

Conclusions:

  • Addition of dronabinol decreased opioid requirements for CIBP in this pilot study.
  • Dronabinol improved patient-reported outcomes, including pain and quality of life.
  • Further investigation into novel analgesics like dronabinol for CIBP is warranted.